BlackRock Inc. Takes Position in Lexeo Therapeutics, Inc. $LXEO

Key Points

• BlackRock acquired 5.74 million Lexeo Therapeutics shares worth approximately $26.7 million, giving it a 7.31% stake. Institutional investors collectively own 60.67% of LXEO.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $18.75 consensus price target, despite JPMorgan cutting its target to $9 and one firm issuing a “Strong Sell” rating.
• LXEO shares opened at $4.78, near their 50-day average, while the company reported a quarterly loss of $0.30 per share—slightly worse than estimates—and insiders sold shares primarily to cover tax obligations.

BlackRock Inc. acquired a new stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 5,739,455 shares of the company's stock, valued at approximately $26,717,000. BlackRock Inc. owned about 7.31% of Lexeo Therapeutics at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Lexeo Therapeutics during the 2nd quarter worth about $1,237,000. Dimensional Fund Advisors LP raised its stake in shares of Lexeo Therapeutics by 27.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,103,584 shares of the company's stock valued at $6,332,000 after acquiring an additional 240,692 shares in the last quarter. Spruce Street Capital LP lifted its holdings in Lexeo Therapeutics by 430.6% in the 1st quarter. Spruce Street Capital LP now owns 928,593 shares of the company's stock worth $5,330,000 after purchasing an additional 753,593 shares during the last quarter. Orbimed Advisors LLC lifted its holdings in Lexeo Therapeutics by 69.5% in the 1st quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company's stock worth $20,678,000 after purchasing an additional 1,477,450 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its position in Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company's stock worth $28,988,000 after purchasing an additional 1,850,211 shares during the period. 60.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LXEO has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating on the stock in a report on Thursday, June 25th. Chardan Capital upgraded shares of Lexeo Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Wall Street Zen downgraded shares of Lexeo Therapeutics from a "hold" rating to a "strong sell" rating in a report on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $18.75.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $4.78 on Thursday. The company has a 50-day simple moving average of $4.73 and a 200-day simple moving average of $5.41. The firm has a market capitalization of $392.20 million, a P/E ratio of -4.16 and a beta of 1.50. Lexeo Therapeutics, Inc. has a 52 week low of $3.99 and a 52 week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.01). As a group, equities analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Insider Activity at Lexeo Therapeutics

In related news, insider Narinder Pal Bhalla sold 22,306 shares of the company's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This represents a 21.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $116,242.56. Following the completion of the transaction, the chief executive officer owned 377,817 shares of the company's stock, valued at $1,692,620.16. The trade was a 6.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 66,326 shares of company stock worth $299,817 in the last three months. 2.00% of the stock is owned by insiders.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

Want to see what other hedge funds are holding LXEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.